Division of Thoracic Surgery, Technical University of Munich, Munich, Germany
Munich, 81675, Germany
NCT Number: NCT02515760
Non-small cell lung cancer is characterized by aggressive growth and treatment resistance. New approaches include immunotherapeutic strategies but spontaneous immune responses against tumor antigens remain unclear. The aim of this study is to characterize localization and frequencies of spontaneously induced memory T cells specific for a panel of tumor-associated antigens in peripheral blood and bone marrow of non-small cell lung cancer patients.
This study is active but is not currently recruiting participants.
Notify Me18 year–79 year
All sexes
Interventional
Not applicable
Munich, 81675, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 weeks postoperative
% of all T cells
Time frame: 2 weeks postoperative
location: peripheral versus bone marrow
Time frame: 5 years postoperative
OS
University Hospital Heidelberg
Other
Tumor-specific Effector T Cells in Non-small Cell Lung Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05132075
Bronchial Neoplasms, Carcinoma, Bronchogenic
Renton, Washington, United States
View Trial DetailsNCT04886804
Bronchial Neoplasms, Carcinoma, Bronchogenic
Birmingham, Alabama, United States
View Trial DetailsNCT05157659
Bronchial Neoplasms, Carcinoma, Bronchogenic
Amsterdam, Nederland, Netherlands
View Trial DetailsNCT04644068
Additional Indications Below for Module 4 and 5, Adnexal Diseases
Boston, Massachusetts, United States
View Trial Details